Biomarker to predict cancer response to chemotherapy

Tech ID: T-015631

Technology Description

Researchers at Washington University in St. Louis have developed a prognostic biomarker that can be used to predict response to genotoxic chemotherapy for patients with basal-like/triple-negative breast cancer. Basal-like/triple-negative breast cancer is considered to be more aggressive and has poorer prognosis than other types of breast cancers. Compared to luminal and Her2-positive breast cancer, few targeted therapies are available for basal-like/triple negative breast cancer. Currently, treatment options include a combination of surgery, radiation, and chemotherapies (most of which are genotoxic). In recent years, newer generation chemotherapeutic agents such as PARP inhibitors show clinical benefit for certain basal-like/triple-negative breast cancer patients. However, the effectiveness of both standard chemotherapies and PARP inhibitors varies greatly between patients. Thus, it would be useful to have a reliable prognostic biomarker to predict patient outcome. To help meet this need the inventors developed a monoclonal antibody, phospho-Ser784-VCP, that can be used to predict genotoxic chemotherapy response. High levels of phospho-Ser784-VCP render tumor cells high ability to survive chemotherapy-induced DNA damage, and correlate with poor survival for chemotherapy-treated patients. With this biomarker patients with higher chance of responding to genotoxic chemotherapies can be selected for treatment. This technology may aid breast cancer treatment as it provides a predictive biomarker for genotoxic chemotherapy response.

Stage of Research

Validation studies conducted by the inventors show great promise.



  • Cancer biomarker- predictive biomarker for genotoxic chemotherapy response

Key Advantages

  • New prognostic biomarker to aid treatment of basal-like/triple-negative breast cancer
  • Stratify patients for chemotherapy treatment
  • Help lower-risk patients avoid over-treatment
  • Prognostic value is independent of clinicopathological variables


  • Patent application has been filed.

Related Web Links




Hardin, Clyde "Frank"

Create a Collection